Novartis is teaming up with R&D leaders throughout the industry as part of the National Institutes of Health (NIH) and the Foundation for NIH (FNIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership initiative. Collaboration and open innovation are essential elements of the fight against this global pandemic. Novartis is committed to doing our part as an active contributor to the global effort underway to combat COVID-19.
About ACTIV
The National Institutes of Health and the Foundation for the NIH are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to develop an international strategy for a coordinated research response to the COVID-19 pandemic. The planned Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.